A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitors

Assay and Drug Development Technologies

Volumn 8, Issue 5, 2010, Pages 571-580

  Scholz, Anne Kathrin ^a   Klebl, Bert M ^b   Morkel, Markus ^a   Lehrach, Hans ^a   Dahl, Andreas ^a   Lange, Bodo M H ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b GPC Biotech AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; BENZOTHIOPHENE DERIVATIVE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DIMETICONE; FLAVOPIRIDOL; PHOSPHOTRANSFERASE INHIBITOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL LINE; CELL VOLUME; CONTROLLED STUDY; DENSITY; GENETIC TRANSFECTION; GENOME; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MAMMAL CELL; MICROARRAY ANALYSIS; MICROSCOPE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CENTROSOME; CERCOPITHECUS AETHIOPS; COS CELLS; DIMETHYLPOLYSILOXANES; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERPHASE; MICROSCOPY, FLUORESCENCE; MITOTIC INDEX; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 77958561850     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0260     Document Type: Article

References (23)

1. Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-166.
2. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-3065.
3. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y: Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999;59:2041-2044.
4. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF: Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106-4111.
5. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, Ecsedy JA: MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27: 4513-4525.
6. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10: 262-267.
7. Tyler RK, Shpiro N, Marquez R, Eyers PA: VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 2007;6:2846-2854.
8. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-11016.
9. Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E: Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996;9:1143-1168.
10. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
11. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-28348.
12. Chao SH, Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-31799.
13. Lange BM, Gull K: A molecular marker for centriole maturation in the mammalian cell cycle. J Cell Biol 1995;130:919-927.
14. Sedlacek HH: Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-170.
15. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, Ye X: Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 2005;579:3385-3391.
16. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-1740.
17. Malumbres M, Barbacid M: Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17:60-65.
18. Klebl BM, Choidas A: CDK9/cyclin T1: a host cell target for antiretroviral therapy. Fut Virol 2006;1:317-330.
19. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI: The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-7677.
20. MacLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y, Franci C, Lang DW, Pali E, Lasaga J, Low C, Zhao F, Chang B, Gururaja TL, Xu W, Baluom M, Sweeny D, Carroll D, Sran A, Thota S, Parmer M, Romane A, Clemens G, Grossbard E, Qu K, Jenkins Y, Kinoshita T, Taylor V, Holland SJ, Argade A, Singh R, Pine P, Payan DG, Hitoshi Y: Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2009;136:99-113.
21. Catalano SM, McLaughlin J, Hitoshi Y, Payan D: Discovery and development of an aurora kinase inhibitor clinical candidate using an image-based assay for measuring proliferation, apoptosis, and DNA content. Assay Drug Dev Technol 2009;7:180-190.
22. DeMoe JH, Santaguida S, Daum JR, Musacchio A, Gorbsky GJ: A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor. Cancer Res 2009;69:1509-1516.
23. Kim JY, Baek JY, Lee KA, Lee SH: Automatic aligning and bonding system of PDMS layer for the fabrication of 3D microfluidic channels. Sens Actuators A Phys 2005;119:593-598.